EA201790438A1 - Антигенсвязывающие белки, которые связываются с cxcr5 - Google Patents
Антигенсвязывающие белки, которые связываются с cxcr5Info
- Publication number
- EA201790438A1 EA201790438A1 EA201790438A EA201790438A EA201790438A1 EA 201790438 A1 EA201790438 A1 EA 201790438A1 EA 201790438 A EA201790438 A EA 201790438A EA 201790438 A EA201790438 A EA 201790438A EA 201790438 A1 EA201790438 A1 EA 201790438A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- cxcr5
- fragments
- derivatives
- polypeptides
- Prior art date
Links
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 title abstract 5
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 title abstract 5
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
Настоящее изобретение относится к композициям и способам, относящимся к или полученным из анти-CXCR5 антител. В частности, настоящее изобретение относится к человеческим антителам, которые связываются с CXCR5, CXCR5-связывающим фрагментам и производным таких антител и CXCR5-связывающим полипептидам, содержащим такие фрагменты. Кроме того, настоящее изобретение относится к нуклеиновым кислотам, кодирующим такие антитела, фрагменты и производные антител и полипептиды, клеткам, содержащим такие полинуклеотиды, способам получения таких антител, фрагментов и производных антител и полипептидов, и способам применения таких антител, фрагментов и производных антител и полипептидов, в том числе к способам лечения или диагностики субъектов, имеющих связанные с CXCR5 нарушения или патологические состояния, включая различные воспалительные заболевания и различные виды рака.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041017P | 2014-08-22 | 2014-08-22 | |
| PCT/US2015/044926 WO2016028573A1 (en) | 2014-08-22 | 2015-08-12 | Antigen binding proteins that bind cxcr5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201790438A1 true EA201790438A1 (ru) | 2017-08-31 |
Family
ID=55347734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790438A EA201790438A1 (ru) | 2014-08-22 | 2015-08-12 | Антигенсвязывающие белки, которые связываются с cxcr5 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9765146B2 (ru) |
| EP (1) | EP3183001A4 (ru) |
| JP (1) | JP2017525710A (ru) |
| KR (1) | KR20170068450A (ru) |
| CN (1) | CN107148281A (ru) |
| AU (1) | AU2015305850A1 (ru) |
| BR (1) | BR112017003472A2 (ru) |
| CA (1) | CA2958674A1 (ru) |
| EA (1) | EA201790438A1 (ru) |
| IL (1) | IL250631A0 (ru) |
| MA (1) | MA40527A (ru) |
| MX (1) | MX2017002381A (ru) |
| PH (1) | PH12017500331A1 (ru) |
| SG (1) | SG11201701375TA (ru) |
| WO (1) | WO2016028573A1 (ru) |
| ZA (1) | ZA201701912B (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016028573A1 (en) | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr5 |
| CA2990076A1 (en) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| IL291308B2 (en) * | 2016-12-21 | 2024-07-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
| WO2018114804A1 (de) * | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| TWI808963B (zh) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗ｃｘｃｒ５抗體治療狼瘡 |
| KR20190131068A (ko) * | 2017-03-22 | 2019-11-25 | 사노피 | 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 |
| EP3672989A1 (en) * | 2017-08-23 | 2020-07-01 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind cxcr5 |
| PE20210554A1 (es) * | 2017-12-01 | 2021-03-17 | Pfizer | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos |
| CN109503712B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns2E11及其应用 |
| KR20210151901A (ko) * | 2019-04-15 | 2021-12-14 | 타르진타 아베 | 인테그린 알파10 및 공격적인 암 형태 |
| WO2023010483A1 (en) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| WO2023014210A1 (en) * | 2021-08-02 | 2023-02-09 | Latvijas Universitate | A device for detection of gastric cancer |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512701B2 (en) * | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
| WO2005019270A2 (en) * | 2003-08-14 | 2005-03-03 | Dyax Corp. | Endotheliase-2 ligands |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US20070266448A1 (en) * | 2006-05-11 | 2007-11-15 | Alexander Lifke | Method for the production of antibodies |
| EP2091975A4 (en) | 2006-11-21 | 2013-05-22 | Univ California | ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE |
| US7807168B2 (en) | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
| CN104017079B (zh) * | 2007-08-29 | 2017-01-04 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| EP2240204A1 (en) * | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| WO2012010582A1 (en) * | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
| CN106432495A (zh) | 2010-07-22 | 2017-02-22 | 加利福尼亚大学董事会 | 抗肿瘤抗原抗体及其使用方法 |
| WO2016028573A1 (en) | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr5 |
-
2015
- 2015-08-12 WO PCT/US2015/044926 patent/WO2016028573A1/en active Application Filing
- 2015-08-12 CN CN201580056533.4A patent/CN107148281A/zh not_active Withdrawn
- 2015-08-12 MA MA040527A patent/MA40527A/fr unknown
- 2015-08-12 SG SG11201701375TA patent/SG11201701375TA/en unknown
- 2015-08-12 KR KR1020177007944A patent/KR20170068450A/ko not_active Withdrawn
- 2015-08-12 EP EP15833683.4A patent/EP3183001A4/en not_active Withdrawn
- 2015-08-12 EA EA201790438A patent/EA201790438A1/ru unknown
- 2015-08-12 CA CA2958674A patent/CA2958674A1/en not_active Abandoned
- 2015-08-12 US US14/825,144 patent/US9765146B2/en active Active
- 2015-08-12 BR BR112017003472A patent/BR112017003472A2/pt not_active Application Discontinuation
- 2015-08-12 AU AU2015305850A patent/AU2015305850A1/en not_active Abandoned
- 2015-08-12 JP JP2017510481A patent/JP2017525710A/ja not_active Withdrawn
- 2015-08-12 MX MX2017002381A patent/MX2017002381A/es unknown
-
2017
- 2017-02-15 IL IL250631A patent/IL250631A0/en unknown
- 2017-02-22 PH PH12017500331A patent/PH12017500331A1/en unknown
- 2017-03-17 ZA ZA2017/01912A patent/ZA201701912B/en unknown
- 2017-08-10 US US15/674,401 patent/US10479837B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107148281A (zh) | 2017-09-08 |
| SG11201701375TA (en) | 2017-03-30 |
| CA2958674A1 (en) | 2016-02-25 |
| BR112017003472A2 (pt) | 2018-01-30 |
| US20160053014A1 (en) | 2016-02-25 |
| AU2015305850A1 (en) | 2017-04-06 |
| MX2017002381A (es) | 2017-09-15 |
| PH12017500331A1 (en) | 2017-07-17 |
| WO2016028573A1 (en) | 2016-02-25 |
| US20170342156A1 (en) | 2017-11-30 |
| EP3183001A4 (en) | 2018-01-17 |
| KR20170068450A (ko) | 2017-06-19 |
| JP2017525710A (ja) | 2017-09-07 |
| ZA201701912B (en) | 2018-05-30 |
| IL250631A0 (en) | 2017-04-30 |
| MA40527A (fr) | 2017-06-28 |
| US10479837B2 (en) | 2019-11-19 |
| US9765146B2 (en) | 2017-09-19 |
| EP3183001A1 (en) | 2017-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790438A1 (ru) | Антигенсвязывающие белки, которые связываются с cxcr5 | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| HK1221964A1 (zh) | 與pd-1結合的抗原結合蛋白 | |
| WO2017015560A3 (en) | Antibody therapeutics that bind lag3 | |
| EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
| HK1255039A1 (zh) | 對pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| MX376808B (es) | Anticuerpos anti-b7-h5 y sus usos. | |
| HK1204557A1 (en) | Antigen binding proteins that bind pd-l1 | |
| PH12016501212A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| MX2016002719A (es) | Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias. | |
| EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
| MX380702B (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| MX373485B (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| HK1214283A1 (zh) | 與erbb3結合的抗原結合蛋白 | |
| PH12017500332A1 (en) | Antigen binding proteins that bind cxcr3 | |
| MA39847A (fr) | Protéines de liaison à l'antigène se liant à wisp1 |